Analyst Derik De Bruin of Bank of America Securities maintained a Hold rating on Hologic (HOLX – Research Report), with a price target of $75.00.
Geoff Meacham has given his Hold rating due to a combination of factors concerning Hologic’s financial performance and market valuation. Hologic’s preliminary financial results for the first quarter of fiscal year 2024 surpassed both Bank of America’s and general market expectations, contributing to a positive outlook on the company’s core business, excluding COVID-related sales. While all segments other than Skeletal showed better than anticipated results, Hologic’s organic sales growth and anticipated earnings per share at the higher end of their guidance suggest a strong business position.
Despite these encouraging signs, Meacham maintains a Neutral stance on the stock, positing that the current share price fairly reflects the value of the company when compared to its peers in the Diagnostics and Medical Technology sectors. This assessment implies that Hologic’s stock may not offer significant upside potential at the current price level, which justifies the Hold recommendation. Additionally, the report anticipates further insights from the company’s upcoming conference presentation, particularly regarding its margins and capital deployment strategies.
See the top stocks recommended by analysts >>
Based on the recent corporate insider activity of 53 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of HOLX in relation to earlier this year.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Hologic (HOLX) Company Description:
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following business segments: Breast Health, Diagnostics, Medical Aesthetics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a broad portfolio of breast imaging and related products and accessories, including digital mammography systems, computer-aided detection, for mammography and minimally invasive breast biopsy devices, breast biopsy site markers, and breast biopsy guidance systems. The Diagnostics segment comprises Aptima family of Assays, target capture/nucleic acid extraction techonolgy, transcription-mediated amplification technology, hybridization protection assay and dual kinetic assat technologies, instrumentation, and Invader Chemistry Platform. The Medical Aesthetics segment offers SculpSure; PicoSure, MedLite, and RevLite; and MonaLisa Touch. The GYN Surgical segment encompasses the NovaSure Endometrial Ablation System and the MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment covers the discovery and horizon X-ray bone densitometry system, an ultrasound-based osteoporosis assessment product, and Fluoroscan mini C-arm imaging products. The company was founded by S. David Ellenbogen and Jay A. Stein in 1986 and is headquartered in Marlborough, MA.
Read More on HOLX:
